ACADVL and fatty liver disease: Reduced NO availability enhances hepatic steatosis through: (1) increased fatty acid synthesis (secondary to enhanced mitochondrial citrate synthesis), and (2) impaired β-oxidation (secondary to reduced S-nitrosylation of very long chain acyl-CoA dehydrogenase (VLCAD)).